Metabolomics profiling reveals distinct signatures in the serum and brain metabolomes in mouse models of Alzheimer’s Disease

Progress in development of efficacious therapies for Alzheimer’s disease (AD) is hampered due to our limited understanding of underlying pathological mechanisms. Increasing evidence suggests that metabolic impairments prior to symptom development can contribute to disease mechanisms and subsequent dementia. Signals in metabolomic pathways conserved across species could provide a promising entry point to translate experimental findings in preclinical mouse models to humans.